ES2894269T3 - Inhibidores macrocíclicos de los virus flaviviridae - Google Patents
Inhibidores macrocíclicos de los virus flaviviridae Download PDFInfo
- Publication number
- ES2894269T3 ES2894269T3 ES18155377T ES18155377T ES2894269T3 ES 2894269 T3 ES2894269 T3 ES 2894269T3 ES 18155377 T ES18155377 T ES 18155377T ES 18155377 T ES18155377 T ES 18155377T ES 2894269 T3 ES2894269 T3 ES 2894269T3
- Authority
- ES
- Spain
- Prior art keywords
- mmol
- alkyl
- compound
- solution
- stirred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(N)NC(C)(C)*=C Chemical compound CC(N)NC(C)(C)*=C 0.000 description 165
- WMBDDTUBUOEKTM-UHFFFAOYSA-N CC(C)(C)OC(N=C)=O Chemical compound CC(C)(C)OC(N=C)=O WMBDDTUBUOEKTM-UHFFFAOYSA-N 0.000 description 2
- WAFRKANDVIZBCC-SGLQPBQASA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1cc2cc(/C=C/C3(C)C)ncc2cc1)=O)=O)=O)OC3=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1cc2cc(/C=C/C3(C)C)ncc2cc1)=O)=O)=O)OC3=O WAFRKANDVIZBCC-SGLQPBQASA-N 0.000 description 2
- LVSYXHXWHDMBGO-ZKGIKYJASA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1nc2cc(/C=C/C3(CC4)CCC4O)ccc2cc1)=O)=O)=O)OC3=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1nc2cc(/C=C/C3(CC4)CCC4O)ccc2cc1)=O)=O)=O)OC3=O LVSYXHXWHDMBGO-ZKGIKYJASA-N 0.000 description 2
- AQIRVIPBAZJQGJ-UHFFFAOYSA-N CCc1cc2cc(C=C)ncc2cc1 Chemical compound CCc1cc2cc(C=C)ncc2cc1 AQIRVIPBAZJQGJ-UHFFFAOYSA-N 0.000 description 2
- LOPKSXMQWBYUOI-BDAKNGLRSA-N N[C@H]1c2ccccc2C[C@H]1O Chemical compound N[C@H]1c2ccccc2C[C@H]1O LOPKSXMQWBYUOI-BDAKNGLRSA-N 0.000 description 2
- QYBQHJATCUQKRL-KUHUBIRLSA-N Bc(cc1)cc2c1ccc([C@@H](C)NC([C@H](CCC1)NN1C(C(C)C)=O)=O)c2 Chemical compound Bc(cc1)cc2c1ccc([C@@H](C)NC([C@H](CCC1)NN1C(C(C)C)=O)=O)c2 QYBQHJATCUQKRL-KUHUBIRLSA-N 0.000 description 1
- JLVPZLUCIDQICW-UHFFFAOYSA-N Bc1ccc(ccc(C(C)=O)n2)c2c1 Chemical compound Bc1ccc(ccc(C(C)=O)n2)c2c1 JLVPZLUCIDQICW-UHFFFAOYSA-N 0.000 description 1
- IQEPJJCCTCPTOC-UHFFFAOYSA-N Bc1ccc(ccc(CC)n2)c2c1 Chemical compound Bc1ccc(ccc(CC)n2)c2c1 IQEPJJCCTCPTOC-UHFFFAOYSA-N 0.000 description 1
- WWBIJUPJIVGSKZ-SSDOTTSWSA-N Bc1ccc(ccc([C@@H](C)O)n2)c2c1 Chemical compound Bc1ccc(ccc([C@@H](C)O)n2)c2c1 WWBIJUPJIVGSKZ-SSDOTTSWSA-N 0.000 description 1
- PAIRORBOLGMJLC-UHFFFAOYSA-N C(c1ccccc1)OC1=[O]=CC11COCCC1 Chemical compound C(c1ccccc1)OC1=[O]=CC11COCCC1 PAIRORBOLGMJLC-UHFFFAOYSA-N 0.000 description 1
- AENUPKDACDOKTN-NXZHAISVSA-N C/C=C(\C)/SCC(/C=N/C)=C Chemical compound C/C=C(\C)/SCC(/C=N/C)=C AENUPKDACDOKTN-NXZHAISVSA-N 0.000 description 1
- CSFZPYLTTMVRCC-NSCUHMNNSA-N C/C=C/C(C1CNC1)=O Chemical compound C/C=C/C(C1CNC1)=O CSFZPYLTTMVRCC-NSCUHMNNSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N C1CCOCC1 Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N C1COCOC1 Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- WPVYSGCSYSHKAE-UHFFFAOYSA-N CC(C(CC1)(CCS1(=O)=O)C(OC)=O)O Chemical compound CC(C(CC1)(CCS1(=O)=O)C(OC)=O)O WPVYSGCSYSHKAE-UHFFFAOYSA-N 0.000 description 1
- UBZLSKLHTOPOBG-UHFFFAOYSA-N CC(C)(C)NN(C)C Chemical compound CC(C)(C)NN(C)C UBZLSKLHTOPOBG-UHFFFAOYSA-N 0.000 description 1
- ILEBPDMKKKPBTJ-UHFFFAOYSA-N CC(C)(C)OC(C1(COC(C)(C)OC1)C=C)=O Chemical compound CC(C)(C)OC(C1(COC(C)(C)OC1)C=C)=O ILEBPDMKKKPBTJ-UHFFFAOYSA-N 0.000 description 1
- OIRPMGYQVWDUJE-BUHFOSPRSA-N CC(C)(C)OC(CCc(cc1)nc2c1ccc(/C=C/C(C)(C)C(OC)=O)c2)=O Chemical compound CC(C)(C)OC(CCc(cc1)nc2c1ccc(/C=C/C(C)(C)C(OC)=O)c2)=O OIRPMGYQVWDUJE-BUHFOSPRSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N CC(C)(C)OC(N)=O Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- RWZJXJUBUVZGHR-UHFFFAOYSA-N CC(C)(C)S(=N)=O Chemical compound CC(C)(C)S(=N)=O RWZJXJUBUVZGHR-UHFFFAOYSA-N 0.000 description 1
- KBHUVVZPDMYBKD-UHFFFAOYSA-N CC(C)(C=C)C(N=O)=O Chemical compound CC(C)(C=C)C(N=O)=O KBHUVVZPDMYBKD-UHFFFAOYSA-N 0.000 description 1
- VUQOIZPFYIVUKD-UHFFFAOYSA-N CC(C)(CC1)CCC1O Chemical compound CC(C)(CC1)CCC1O VUQOIZPFYIVUKD-UHFFFAOYSA-N 0.000 description 1
- XQHJTHNUMIJXHW-UHFFFAOYSA-N CC(C)(CC1)CCC1OC(C)=O Chemical compound CC(C)(CC1)CCC1OC(C)=O XQHJTHNUMIJXHW-UHFFFAOYSA-N 0.000 description 1
- LZUJKVQFTXMNRQ-UHFFFAOYSA-N CC(C)(CC1)CCN1S(C)(O)=O Chemical compound CC(C)(CC1)CCN1S(C)(O)=O LZUJKVQFTXMNRQ-UHFFFAOYSA-N 0.000 description 1
- JRFXQKZEGILCCO-UHFFFAOYSA-N CC(C)(CO1)COC1=O Chemical compound CC(C)(CO1)COC1=O JRFXQKZEGILCCO-UHFFFAOYSA-N 0.000 description 1
- QOUQIEMSMPSHQK-BYPYZUCNSA-N CC(C)(O[C@H]1CC(F)F)OC1=O Chemical compound CC(C)(O[C@H]1CC(F)F)OC1=O QOUQIEMSMPSHQK-BYPYZUCNSA-N 0.000 description 1
- QOZPDPCIZRWBKN-GSVOUGTGSA-N CC(C)([C@@H](C(O)=O)O)F Chemical compound CC(C)([C@@H](C(O)=O)O)F QOZPDPCIZRWBKN-GSVOUGTGSA-N 0.000 description 1
- SBQJMEFFWMAILI-VMPITWQZSA-N CC(C)C(C(NC(C)C(N(CCC1)NC1C(NC(C)c1ccc(ccc(/C=C/CCC(CC2)O)c3)c3n1)=O)=O)=O)OC2=O Chemical compound CC(C)C(C(NC(C)C(N(CCC1)NC1C(NC(C)c1ccc(ccc(/C=C/CCC(CC2)O)c3)c3n1)=O)=O)=O)OC2=O SBQJMEFFWMAILI-VMPITWQZSA-N 0.000 description 1
- LVSYXHXWHDMBGO-SDNWHVSQSA-N CC(C)C(C(NC(C)C(N(CCC1)NC1C(NC(C)c1nc2cc(/C=C/C3(CC4)CCC4O)ccc2cc1)=O)=O)=O)OC3=O Chemical compound CC(C)C(C(NC(C)C(N(CCC1)NC1C(NC(C)c1nc2cc(/C=C/C3(CC4)CCC4O)ccc2cc1)=O)=O)=O)OC3=O LVSYXHXWHDMBGO-SDNWHVSQSA-N 0.000 description 1
- UZKJBXJPWKHZPC-SDNWHVSQSA-N CC(C)C(C(NC(C)C(N(CCC1)NC1C(NC(C)c1nc2cc(/C=C/C3(CC4)CCC4O)ccc2cc1)O)=O)=O)OC3=O Chemical compound CC(C)C(C(NC(C)C(N(CCC1)NC1C(NC(C)c1nc2cc(/C=C/C3(CC4)CCC4O)ccc2cc1)O)=O)=O)OC3=O UZKJBXJPWKHZPC-SDNWHVSQSA-N 0.000 description 1
- AWRUHVGIJHVGMH-SWIUTLGTSA-N CC(C)C(C(N[C@@H](C)C(N(CCC1)NC1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/OCC(C)(C)OC1)c2)=O)=O)=O)OC1=O Chemical compound CC(C)C(C(N[C@@H](C)C(N(CCC1)NC1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/OCC(C)(C)OC1)c2)=O)=O)=O)OC1=O AWRUHVGIJHVGMH-SWIUTLGTSA-N 0.000 description 1
- AEVCLPJXNJZNHJ-BSSGAZNRSA-N CC(C)C(C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(NCc1nc2cc(/C=C/C3(C)C)ccc2cc1)=O)=O)=O)OC3=O Chemical compound CC(C)C(C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(NCc1nc2cc(/C=C/C3(C)C)ccc2cc1)=O)=O)=O)OC3=O AEVCLPJXNJZNHJ-BSSGAZNRSA-N 0.000 description 1
- RNZYMNILBJJGNI-UHFFFAOYSA-N CC(C)C(C)(C1)OCCN1S(C)(=O)=O Chemical compound CC(C)C(C)(C1)OCCN1S(C)(=O)=O RNZYMNILBJJGNI-UHFFFAOYSA-N 0.000 description 1
- MREUJWXYTKIPBR-UHFFFAOYSA-N CC(C)C(C)(CC1)CCC1O Chemical compound CC(C)C(C)(CC1)CCC1O MREUJWXYTKIPBR-UHFFFAOYSA-N 0.000 description 1
- XDMZUSFVVQWSSC-UHFFFAOYSA-N CC(C)C1(C)COC(CF)(CF)OC1 Chemical compound CC(C)C1(C)COC(CF)(CF)OC1 XDMZUSFVVQWSSC-UHFFFAOYSA-N 0.000 description 1
- VYWGPDGABKMCMK-UHFFFAOYSA-N CC(C)C1=CCCC(C=C)=C1 Chemical compound CC(C)C1=CCCC(C=C)=C1 VYWGPDGABKMCMK-UHFFFAOYSA-N 0.000 description 1
- NTTHZBMZZUXETK-ZFWKYDESSA-N CC(C)[C@@H](C(N(C)[C@@H](C)C([C@@H](CCC1)N[C@@H]1C(N[C@@H](C)c1cc(C=C)ccc1)=O)=O)=O)OC([C@H](C)C(CCC=C)OC)=O Chemical compound CC(C)[C@@H](C(N(C)[C@@H](C)C([C@@H](CCC1)N[C@@H]1C(N[C@@H](C)c1cc(C=C)ccc1)=O)=O)=O)OC([C@H](C)C(CCC=C)OC)=O NTTHZBMZZUXETK-ZFWKYDESSA-N 0.000 description 1
- QQIZTRRYHFBZBY-XNFYSYIQSA-N CC(C)[C@@H](C(N)=O)/N=C/CCCC=C Chemical compound CC(C)[C@@H](C(N)=O)/N=C/CCCC=C QQIZTRRYHFBZBY-XNFYSYIQSA-N 0.000 description 1
- CCNMBAGDQPORAX-CCYZICQQSA-N CC(C)[C@@H](C(NC(C(N(CCC1)NC1C(O[C@@H]1C)=O)=O)=C)=O)OCC(C)/C=C/C2=CC=C3C=CC1=NC3C2 Chemical compound CC(C)[C@@H](C(NC(C(N(CCC1)NC1C(O[C@@H]1C)=O)=O)=C)=O)OCC(C)/C=C/C2=CC=C3C=CC1=NC3C2 CCNMBAGDQPORAX-CCYZICQQSA-N 0.000 description 1
- WDSDZTRNCSJVKV-NTZQROQTSA-N CC(C)[C@@H](C(NC(C(N(CCC1)N[C@@H]1C(O)=O)=O)=C)O)OC(CCc(cc1)ccc1C1=CCC(CC(NC(OC(C)(C)C)=O)=C)C=C1)=O Chemical compound CC(C)[C@@H](C(NC(C(N(CCC1)N[C@@H]1C(O)=O)=O)=C)O)OC(CCc(cc1)ccc1C1=CCC(CC(NC(OC(C)(C)C)=O)=C)C=C1)=O WDSDZTRNCSJVKV-NTZQROQTSA-N 0.000 description 1
- ALSWRWQXFWCGEC-OGDDMESBSA-N CC(C)[C@@H](C(NC(C(N(CCC1)N[C@]1(C)C(N[C@H](C)C1Nc2cc(/C=C/C3(CC4)CCC4O)ccc2C=C1)=O)=O)=C)=O)OC3=O Chemical compound CC(C)[C@@H](C(NC(C(N(CCC1)N[C@]1(C)C(N[C@H](C)C1Nc2cc(/C=C/C3(CC4)CCC4O)ccc2C=C1)=O)=O)=C)=O)OC3=O ALSWRWQXFWCGEC-OGDDMESBSA-N 0.000 description 1
- HEMJJPYQWSAKKX-OOFGLCLZSA-N CC(C)[C@@H](C(N[C@@H](C)C(C(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(/C=C/C2(C)[I-]OC)c3)c3c1)=O)=O)=O)OC2=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(C(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(/C=C/C2(C)[I-]OC)c3)c3c1)=O)=O)=O)OC2=O HEMJJPYQWSAKKX-OOFGLCLZSA-N 0.000 description 1
- AWIZKZSTINLJIJ-AJYMSZOXSA-N CC(C)[C@@H](C(N[C@@H](C)C(C(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(/C=C/[C@]2(C)COC(F)(F)F)c3)c3c1)=O)=O)=O)OC2=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(C(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(/C=C/[C@]2(C)COC(F)(F)F)c3)c3c1)=O)=O)=O)OC2=O AWIZKZSTINLJIJ-AJYMSZOXSA-N 0.000 description 1
- NECBOCDAOLVPFY-RKLVZMDXSA-N CC(C)[C@@H](C(N[C@@H](C)C(C(CCCC1)N[C@@H]1C(OCC(Cl)(Cl)Cl)=O)=O)=O)O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(C(CCCC1)N[C@@H]1C(OCC(Cl)(Cl)Cl)=O)=O)=O)O NECBOCDAOLVPFY-RKLVZMDXSA-N 0.000 description 1
- AEVCLPJXNJZNHJ-QJFFZHFZSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)NC1C(NCc1nc2cc(/C=C/C3(C)C)ccc2cc1)=O)=O)=O)OC3=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)NC1C(NCc1nc2cc(/C=C/C3(C)C)ccc2cc1)=O)=O)=O)OC3=O AEVCLPJXNJZNHJ-QJFFZHFZSA-N 0.000 description 1
- KICVJJBJJBUSSG-JBFJVSFMSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)C1N=C(C=C(C=C2)/C=C/CC[C@@H](CC3)O)C2=CC1)O)O)=O)OC3=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)C1N=C(C=C(C=C2)/C=C/CC[C@@H](CC3)O)C2=CC1)O)O)=O)OC3=O KICVJJBJJBUSSG-JBFJVSFMSA-N 0.000 description 1
- SBQJMEFFWMAILI-ZDKUCFCQSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/CC[C@@H](CC1)O)c2)=O)=O)=O)OC1=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/CC[C@@H](CC1)O)c2)=O)=O)=O)OC1=O SBQJMEFFWMAILI-ZDKUCFCQSA-N 0.000 description 1
- UCMHQUAUKCKDLC-ITIOGAGCSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c(cc1)nc2c1ccc(Br)c2)=O)=O)=O)O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c(cc1)nc2c1ccc(Br)c2)=O)=O)=O)O UCMHQUAUKCKDLC-ITIOGAGCSA-N 0.000 description 1
- IPYCONBYPXKVJQ-RYSSLDFJSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1cc(/C=C/CCC([C@H]2C)OC3C(C)(C)C3)ccc1)=O)=O)=O)OC2=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1cc(/C=C/CCC([C@H]2C)OC3C(C)(C)C3)ccc1)=O)=O)=O)OC2=O IPYCONBYPXKVJQ-RYSSLDFJSA-N 0.000 description 1
- XDQVUFONAXIYQY-RZONWFCTSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1cc2cc(/C=C/[C@@]3(C)COC)ccc2cc1)=O)=O)=O)OC3=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1cc2cc(/C=C/[C@@]3(C)COC)ccc2cc1)=O)=O)=O)OC3=O XDQVUFONAXIYQY-RZONWFCTSA-N 0.000 description 1
- SBQJMEFFWMAILI-NZTKHXDESA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(/C=C/CC[C@H](CC2)O)c3)c3n1)=O)=O)=O)OC2=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(/C=C/CC[C@H](CC2)O)c3)c3n1)=O)=O)=O)OC2=O SBQJMEFFWMAILI-NZTKHXDESA-N 0.000 description 1
- VAZQJRBVEOBRET-ITIOGAGCSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(S)c2)c2n1)=O)=O)=O)O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(S)c2)c2n1)=O)=O)=O)O VAZQJRBVEOBRET-ITIOGAGCSA-N 0.000 description 1
- LQRYIABNSWACTA-KJKRJXCASA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1nc2cc(/C=C/C3(CC4)CCS4(O)=O)ccc2cc1)=O)=O)=O)OC3=O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1nc2cc(/C=C/C3(CC4)CCS4(O)=O)ccc2cc1)=O)=O)=O)OC3=O LQRYIABNSWACTA-KJKRJXCASA-N 0.000 description 1
- HDBPRXSELBZTKU-DCAQKATOSA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(OC)=O)=O)=O)O Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(OC)=O)=O)=O)O HDBPRXSELBZTKU-DCAQKATOSA-N 0.000 description 1
- ZIWYKJOQZGNFJM-GDRDMMFISA-N CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(OC)=O)=O)=O)OCC(C)/C=C/c1cc(nc(C(C)C)cc2)c2cc1 Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(OC)=O)=O)=O)OCC(C)/C=C/c1cc(nc(C(C)C)cc2)c2cc1 ZIWYKJOQZGNFJM-GDRDMMFISA-N 0.000 description 1
- DMLLORUEBDNSHR-GMLIWBFZSA-O CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C([SH+]C(C)c1cc2cc(C=C)ncc2cc1)=O)=O)=O)OCCCC=C Chemical compound CC(C)[C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C([SH+]C(C)c1cc2cc(C=C)ncc2cc1)=O)=O)=O)OCCCC=C DMLLORUEBDNSHR-GMLIWBFZSA-O 0.000 description 1
- SBQJMEFFWMAILI-DIBUQOLQSA-N CC(C)[C@H](C(N[C@@H](C)C(N(CCC1)NC1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/CC[C@@H](CC1)O)c2)=O)=O)=O)OC1=O Chemical compound CC(C)[C@H](C(N[C@@H](C)C(N(CCC1)NC1C(N[C@H](C)c(cc1)nc2c1ccc(/C=C/CC[C@@H](CC1)O)c2)=O)=O)=O)OC1=O SBQJMEFFWMAILI-DIBUQOLQSA-N 0.000 description 1
- SBQJMEFFWMAILI-LFUSBINHSA-N CC(C)[C@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(/C=C/CC[C@H](CC2)O)c3)c3n1)=O)=O)=O)OC2=O Chemical compound CC(C)[C@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(/C=C/CC[C@H](CC2)O)c3)c3n1)=O)=O)=O)OC2=O SBQJMEFFWMAILI-LFUSBINHSA-N 0.000 description 1
- DBSTVOYFFBWIAF-YZXZPUIHSA-N CC(C)[C@H](C(OC)=O)/N=C/C(F)(F)F Chemical compound CC(C)[C@H](C(OC)=O)/N=C/C(F)(F)F DBSTVOYFFBWIAF-YZXZPUIHSA-N 0.000 description 1
- ZWHGNXDGBCNTMR-QDFRJQGMSA-N CC(C)[C@H](C)C(N[C@@H](C)C(C(CCC1)N[C@@H]1C(NCc(cc1)nc2c1ccc(/C=C/C(C)(C)C(OC)=O)c2)=O)=O)=O Chemical compound CC(C)[C@H](C)C(N[C@@H](C)C(C(CCC1)N[C@@H]1C(NCc(cc1)nc2c1ccc(/C=C/C(C)(C)C(OC)=O)c2)=O)=O)=O ZWHGNXDGBCNTMR-QDFRJQGMSA-N 0.000 description 1
- YIDRCDVUTAKAAP-UHFFFAOYSA-N CC(C1(C(OC)=O)OCCOC1)O Chemical compound CC(C1(C(OC)=O)OCCOC1)O YIDRCDVUTAKAAP-UHFFFAOYSA-N 0.000 description 1
- URMMUKOUTROPBW-UHFFFAOYSA-N CC(C1(COCCC1)C(OCc1ccccc1)=O)OS(C(F)(F)F)(=O)=O Chemical compound CC(C1(COCCC1)C(OCc1ccccc1)=O)OS(C(F)(F)F)(=O)=O URMMUKOUTROPBW-UHFFFAOYSA-N 0.000 description 1
- KTCMZKJEAHWWSR-UHFFFAOYSA-N CC(NC)N(C)N Chemical compound CC(NC)N(C)N KTCMZKJEAHWWSR-UHFFFAOYSA-N 0.000 description 1
- PMIRMVUEKZBGRA-KXVGNKNLSA-N CC([C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(/C=C/C2(C)C)c3)c3n1)=O)=O)=O)OC2=O)C(F)(F)F Chemical compound CC([C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1ccc(ccc(/C=C/C2(C)C)c3)c3n1)=O)=O)=O)OC2=O)C(F)(F)F PMIRMVUEKZBGRA-KXVGNKNLSA-N 0.000 description 1
- IRPAZYFCXUOYLJ-RKLVZMDXSA-N CC([C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(OCC(Cl)(Cl)Cl)=O)=O)=O)O)OC(C)(C)C Chemical compound CC([C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(OCC(Cl)(Cl)Cl)=O)=O)=O)O)OC(C)(C)C IRPAZYFCXUOYLJ-RKLVZMDXSA-N 0.000 description 1
- AKWULRQHXZPPNH-DQRVPFMQSA-N CC([C@H](C)c(cc1)nc2c1ccc(/C=C/C(C)(C)C(O)=O)c2)C(OC(C)(C)C)=O Chemical compound CC([C@H](C)c(cc1)nc2c1ccc(/C=C/C(C)(C)C(O)=O)c2)C(OC(C)(C)C)=O AKWULRQHXZPPNH-DQRVPFMQSA-N 0.000 description 1
- UMAPQWCKTLVUDF-PXCRVHGXSA-N CC([C@H](CC[C@@H]1C(C)(C)/C=C/c2cc(nc([C@@H](C)OC([C@H](CCC3)NN3C([C@H](C)N3)=O)=O)cc4)c4cc2)C3=O)[F]C1(F)F Chemical compound CC([C@H](CC[C@@H]1C(C)(C)/C=C/c2cc(nc([C@@H](C)OC([C@H](CCC3)NN3C([C@H](C)N3)=O)=O)cc4)c4cc2)C3=O)[F]C1(F)F UMAPQWCKTLVUDF-PXCRVHGXSA-N 0.000 description 1
- LUCMDBVNPZBBAF-MDZDMXLPSA-N CC(c(cc1)nc2c1ccc(/C=C/C1(COCOC1)C(O)=O)c2)NC(OC(C)(C)C)=O Chemical compound CC(c(cc1)nc2c1ccc(/C=C/C1(COCOC1)C(O)=O)c2)NC(OC(C)(C)C)=O LUCMDBVNPZBBAF-MDZDMXLPSA-N 0.000 description 1
- VOEIMODQGCAHJZ-JCVRYMFTSA-N CC(c1cc(/C=C/CCC(NC(C(C23N[C@H]4CCCC2C3)=O)=C)O)ccc1)NC4=O Chemical compound CC(c1cc(/C=C/CCC(NC(C(C23N[C@H]4CCCC2C3)=O)=C)O)ccc1)NC4=O VOEIMODQGCAHJZ-JCVRYMFTSA-N 0.000 description 1
- WAMZNXBCYMTGHB-UHFFFAOYSA-N CC(c1nc2cc(Br)ccc2cc1)=O Chemical compound CC(c1nc2cc(Br)ccc2cc1)=O WAMZNXBCYMTGHB-UHFFFAOYSA-N 0.000 description 1
- YUQDJBKEDAWMOG-UJPCXNRSSA-N CC/C=C(/C1)\[C@@H](CC2=CC=CCC2)COC1=C Chemical compound CC/C=C(/C1)\[C@@H](CC2=CC=CCC2)COC1=C YUQDJBKEDAWMOG-UJPCXNRSSA-N 0.000 description 1
- IECMOFZIMWVOAS-UHFFFAOYSA-N CC1(C)CCNCC1 Chemical compound CC1(C)CCNCC1 IECMOFZIMWVOAS-UHFFFAOYSA-N 0.000 description 1
- JGIIAGKXWSQLOG-UHFFFAOYSA-N CC1(C)COCCC1 Chemical compound CC1(C)COCCC1 JGIIAGKXWSQLOG-UHFFFAOYSA-N 0.000 description 1
- QDCJIPFNVBDLRH-UHFFFAOYSA-N CC1(C)COCOC1 Chemical compound CC1(C)COCOC1 QDCJIPFNVBDLRH-UHFFFAOYSA-N 0.000 description 1
- PIXUVHQRRAVCHB-UHFFFAOYSA-N CC1(C)N(C)C(C=C)=CC1=C Chemical compound CC1(C)N(C)C(C=C)=CC1=C PIXUVHQRRAVCHB-UHFFFAOYSA-N 0.000 description 1
- BGHGGJKXOXOFFD-UHFFFAOYSA-N CC1(C)OCC(C)(C)OC1 Chemical compound CC1(C)OCC(C)(C)OC1 BGHGGJKXOXOFFD-UHFFFAOYSA-N 0.000 description 1
- FFFKCZWTCWRIPW-UHFFFAOYSA-N CC1(C)OCC(C=C)(C(OCc2ccccc2)=O)OC1 Chemical compound CC1(C)OCC(C=C)(C(OCc2ccccc2)=O)OC1 FFFKCZWTCWRIPW-UHFFFAOYSA-N 0.000 description 1
- SWZUJPXFLKZGLI-UHFFFAOYSA-N CC1(C)OCCCC1 Chemical compound CC1(C)OCCCC1 SWZUJPXFLKZGLI-UHFFFAOYSA-N 0.000 description 1
- RPLSBADGISFNSI-UHFFFAOYSA-N CC1(C)OCCCO1 Chemical compound CC1(C)OCCCO1 RPLSBADGISFNSI-UHFFFAOYSA-N 0.000 description 1
- CJIJQMIHJBCLAR-UHFFFAOYSA-N CCC#CC1(CCOCC1)C(O)OC Chemical compound CCC#CC1(CCOCC1)C(O)OC CJIJQMIHJBCLAR-UHFFFAOYSA-N 0.000 description 1
- ODRAIYFKSNQUTP-ZXXJYSGJSA-N CCC(CCC1OC1C(O[C@@H](C(C)C)C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)C(C=C1)=C2C3C2)=O)=C)=N)=N)CC/C=C\c2ccc1c3c2 Chemical compound CCC(CCC1OC1C(O[C@@H](C(C)C)C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)C(C=C1)=C2C3C2)=O)=C)=N)=N)CC/C=C\c2ccc1c3c2 ODRAIYFKSNQUTP-ZXXJYSGJSA-N 0.000 description 1
- UUGREXSFBFIBQZ-UXZRVVEMSA-N CCC([C@H](C)C(N(C1)C(C)(C)C(OC)=O)=CC=C1/C=C\CC)C(OC(C)(C)C)=O Chemical compound CCC([C@H](C)C(N(C1)C(C)(C)C(OC)=O)=CC=C1/C=C\CC)C(OC(C)(C)C)=O UUGREXSFBFIBQZ-UXZRVVEMSA-N 0.000 description 1
- BMLYRJOYQDJMOR-UHFFFAOYSA-N CCC1=CC=CC1(C)C Chemical compound CCC1=CC=CC1(C)C BMLYRJOYQDJMOR-UHFFFAOYSA-N 0.000 description 1
- LPMFYRRZAOCGEI-SXUMXUFMSA-N CCCC(OC(CC1)CCC1(/C=C/c1cc2nc([C@@H](C)NC([C@H](CCC3)NN3C([C@H](C)NC([C@H](C(C)C)O3)=O)=O)=O)ccc2cc1)C3=O)=O Chemical compound CCCC(OC(CC1)CCC1(/C=C/c1cc2nc([C@@H](C)NC([C@H](CCC3)NN3C([C@H](C)NC([C@H](C(C)C)O3)=O)=O)=O)ccc2cc1)C3=O)=O LPMFYRRZAOCGEI-SXUMXUFMSA-N 0.000 description 1
- FJCLLGXHFFCQNP-CFMCSPIPSA-N CCCCC(C([C@@H](Cc1ccccc1)CO1)C1=O)=O Chemical compound CCCCC(C([C@@H](Cc1ccccc1)CO1)C1=O)=O FJCLLGXHFFCQNP-CFMCSPIPSA-N 0.000 description 1
- SPQHYPMUSSTHKZ-UHFFFAOYSA-N CCN1CC(C)(C)OCC1 Chemical compound CCN1CC(C)(C)OCC1 SPQHYPMUSSTHKZ-UHFFFAOYSA-N 0.000 description 1
- UCOPGGKTXBQBNI-UHFFFAOYSA-N CCOC(c1cc2cc(O)ncc2cc1)=C Chemical compound CCOC(c1cc2cc(O)ncc2cc1)=C UCOPGGKTXBQBNI-UHFFFAOYSA-N 0.000 description 1
- WYAOYCMOICSHHQ-DCUFJWGLSA-N CCO[C@@H](C(C)C)C(N[C@@H](C)C(CC1(CCC[C@H]2C(N=C)=O)C22N[C@@H]12)O)=O Chemical compound CCO[C@@H](C(C)C)C(N[C@@H](C)C(CC1(CCC[C@H]2C(N=C)=O)C22N[C@@H]12)O)=O WYAOYCMOICSHHQ-DCUFJWGLSA-N 0.000 description 1
- QZDHORFJZVYIIM-IHRRRGAJSA-N CC[C@H](C)C(C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(OCC(C)(C)C)=O)=O)=O)=[NH+][O-] Chemical compound CC[C@H](C)C(C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(OCC(C)(C)C)=O)=O)=O)=[NH+][O-] QZDHORFJZVYIIM-IHRRRGAJSA-N 0.000 description 1
- NFOMBLRCDZKLPU-WHFBIAKZSA-N CC[C@H](C)[C@@H](C(N=O)=O)O Chemical compound CC[C@H](C)[C@@H](C(N=O)=O)O NFOMBLRCDZKLPU-WHFBIAKZSA-N 0.000 description 1
- SATWUKLYJFEJEF-UHFFFAOYSA-N CC[O](CC)CC(C)N Chemical compound CC[O](CC)CC(C)N SATWUKLYJFEJEF-UHFFFAOYSA-N 0.000 description 1
- XCUYHZUHBZRSGY-BYQRAHIRSA-N CCc(cc1)cc2c1cnc(/C=C/CC(C)(C)C1=[O]C(C)[C@@H](C(NC(C)C(N(CCC3)N[C@@H]3C(N)=O)=O)=O)O1)c2 Chemical compound CCc(cc1)cc2c1cnc(/C=C/CC(C)(C)C1=[O]C(C)[C@@H](C(NC(C)C(N(CCC3)N[C@@H]3C(N)=O)=O)=O)O1)c2 XCUYHZUHBZRSGY-BYQRAHIRSA-N 0.000 description 1
- SUKRIXPHVXZZOF-HJKZNEBBSA-N CCc(cc1)cc2c1cnc(/C=C/CCCNC(C(NC(N(CCC1)N[C@@H]1C(O)=O)=C)=O)=C(C)C)c2 Chemical compound CCc(cc1)cc2c1cnc(/C=C/CCCNC(C(NC(N(CCC1)N[C@@H]1C(O)=O)=C)=O)=C(C)C)c2 SUKRIXPHVXZZOF-HJKZNEBBSA-N 0.000 description 1
- CMVSMEBCUWWTEV-MDZDMXLPSA-N CCc(cc1)nc2c1ccc(/C=C/C(C)(C)C(O)=O)c2 Chemical compound CCc(cc1)nc2c1ccc(/C=C/C(C)(C)C(O)=O)c2 CMVSMEBCUWWTEV-MDZDMXLPSA-N 0.000 description 1
- PDUCRBCEPAJEIL-CDOKQYEBSA-N CCc(cc1)nc2c1ccc(/C=C/C(C)(C)C(O[C@@H](C1CC1)C(NC(C(N(CCC1)N[C@@H]1C(N=C)=O)O)=C)=O)=O)c2 Chemical compound CCc(cc1)nc2c1ccc(/C=C/C(C)(C)C(O[C@@H](C1CC1)C(NC(C(N(CCC1)N[C@@H]1C(N=C)=O)O)=C)=O)=O)c2 PDUCRBCEPAJEIL-CDOKQYEBSA-N 0.000 description 1
- LKYHUHSLNBELAP-BIRMXLJFSA-N CCc(cc1)nc2c1ccc(/C=C/C1(CCCCC1)C(O[C@@H](C(C)C)C(N[C@@H](C)C(NN)=O)=O)=O)c2 Chemical compound CCc(cc1)nc2c1ccc(/C=C/C1(CCCCC1)C(O[C@@H](C(C)C)C(N[C@@H](C)C(NN)=O)=O)=O)c2 LKYHUHSLNBELAP-BIRMXLJFSA-N 0.000 description 1
- ODMLZXAJFGFOOQ-UHFFFAOYSA-O CCc(cc1)nc2c1ccc(C=CC(C)(C)C(OC(C(C)C)C(NC(CO)C(N(CC(C1)c3cc([S-](C(C)(C)C)c4ccccc4)ccc3)NC1C([NH2+]C)=O)=O)=O)=O)c2 Chemical compound CCc(cc1)nc2c1ccc(C=CC(C)(C)C(OC(C(C)C)C(NC(CO)C(N(CC(C1)c3cc([S-](C(C)(C)C)c4ccccc4)ccc3)NC1C([NH2+]C)=O)=O)=O)=O)c2 ODMLZXAJFGFOOQ-UHFFFAOYSA-O 0.000 description 1
- KTMFWORWXFBUHB-UHFFFAOYSA-N CCc1ccc(ccc(B=C)c2)c2c1C Chemical compound CCc1ccc(ccc(B=C)c2)c2c1C KTMFWORWXFBUHB-UHFFFAOYSA-N 0.000 description 1
- KVUFWGSDRRKUDF-PDRIIKIYSA-N CCc1cccc(/C=C/CC[C@@H](CCOC)[C@@H](C)C(O[C@@H](C(C)C)C(N[C@@H](C)C(NCCC[C@@H](C([N]#C)=O)OC)=C)=O)=O)c1 Chemical compound CCc1cccc(/C=C/CC[C@@H](CCOC)[C@@H](C)C(O[C@@H](C(C)C)C(N[C@@H](C)C(NCCC[C@@H](C([N]#C)=O)OC)=C)=O)=O)c1 KVUFWGSDRRKUDF-PDRIIKIYSA-N 0.000 description 1
- WNHQDLCMMPGKOD-DUBDHOBOSA-N CCc1nc(cc(CC(C)C(C)(C)C(O[C@@H](C(C)C)C(C2(CC2)[C@@H](COC)C(C)N(CCC2)N[C@@H]2C(C2C=C2)=O)=O)=O)cc2)c2cc1 Chemical compound CCc1nc(cc(CC(C)C(C)(C)C(O[C@@H](C(C)C)C(C2(CC2)[C@@H](COC)C(C)N(CCC2)N[C@@H]2C(C2C=C2)=O)=O)=O)cc2)c2cc1 WNHQDLCMMPGKOD-DUBDHOBOSA-N 0.000 description 1
- BNXYSPNMXNGYIM-UHFFFAOYSA-N COC(C(CC1)(CCS1(=O)=O)C=C)=O Chemical compound COC(C(CC1)(CCS1(=O)=O)C=C)=O BNXYSPNMXNGYIM-UHFFFAOYSA-N 0.000 description 1
- CNCMVGXVKBJYNU-UHFFFAOYSA-N COC(C1CCOCC1)=O Chemical compound COC(C1CCOCC1)=O CNCMVGXVKBJYNU-UHFFFAOYSA-N 0.000 description 1
- RZINJPRFHLZTNT-UHFFFAOYSA-N COC(C1OCCOC1)=O Chemical compound COC(C1OCCOC1)=O RZINJPRFHLZTNT-UHFFFAOYSA-N 0.000 description 1
- OTHWPJJVZAPVKF-UHFFFAOYSA-N COC1(C2OCCOC2)OC1 Chemical compound COC1(C2OCCOC2)OC1 OTHWPJJVZAPVKF-UHFFFAOYSA-N 0.000 description 1
- NHFXQLXGYUKMKW-UHFFFAOYSA-N CSC(C(CC1)(CCC1=O)C=C)=O Chemical compound CSC(C(CC1)(CCC1=O)C=C)=O NHFXQLXGYUKMKW-UHFFFAOYSA-N 0.000 description 1
- HCNQPJOLWSVKNP-OPVGJYCPSA-N C[C@@H](C(N(CCC1)NC1C(NCc(cc1)nc2c1ccc(/C=C/C(C)(C)/C(/O)=[O]\OC1=C(C)C)c2)=O)=O)NC1=O Chemical compound C[C@@H](C(N(CCC1)NC1C(NCc(cc1)nc2c1ccc(/C=C/C(C)(C)/C(/O)=[O]\OC1=C(C)C)c2)=O)=O)NC1=O HCNQPJOLWSVKNP-OPVGJYCPSA-N 0.000 description 1
- VXMBLAZOYGQCQO-BQBZGAKWSA-N C[C@@H](C(N(CCC1)N[C@@H]1C(OCC(Cl)(Cl)Cl)=O)=O)N Chemical compound C[C@@H](C(N(CCC1)N[C@@H]1C(OCC(Cl)(Cl)Cl)=O)=O)N VXMBLAZOYGQCQO-BQBZGAKWSA-N 0.000 description 1
- KYPFCGNQEYKVCI-UWVGGRQHSA-N C[C@@H](C(N(CCC1)N[C@@H]1C(OCC(Cl)(Cl)Cl)=O)=O)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C(N(CCC1)N[C@@H]1C(OCC(Cl)(Cl)Cl)=O)=O)NC(OC(C)(C)C)=O KYPFCGNQEYKVCI-UWVGGRQHSA-N 0.000 description 1
- UGNDBFOSVKDSIZ-UWVGGRQHSA-N C[C@@H](C(N(CCC1)N[C@@H]1C(OCC(N)(Cl)Cl)=O)=O)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C(N(CCC1)N[C@@H]1C(OCC(N)(Cl)Cl)=O)=O)NC(OC(C)(C)C)=O UGNDBFOSVKDSIZ-UWVGGRQHSA-N 0.000 description 1
- XPHYPXLHJSNICK-VFCDZSJCSA-N C[C@@H](C(N(CCC1/C=C/C(C)(C)C(OC(C2COC2)C(O)=O)=O)N[C@@H]1C(NC(C)c1nc(cc(C)cc2)c2cc1)=O)=O)NC(C(C1COC1)OC(C(C)(C)C=C)=O)=O Chemical compound C[C@@H](C(N(CCC1/C=C/C(C)(C)C(OC(C2COC2)C(O)=O)=O)N[C@@H]1C(NC(C)c1nc(cc(C)cc2)c2cc1)=O)=O)NC(C(C1COC1)OC(C(C)(C)C=C)=O)=O XPHYPXLHJSNICK-VFCDZSJCSA-N 0.000 description 1
- SNZXYPAVQAGIES-GARJFASQSA-N C[C@@H](C(NCCC[C@@H](C(OCC(N)(Cl)Cl)=O)N)=O)NC([C@H](C(C)(C)C)O)=O Chemical compound C[C@@H](C(NCCC[C@@H](C(OCC(N)(Cl)Cl)=O)N)=O)NC([C@H](C(C)(C)C)O)=O SNZXYPAVQAGIES-GARJFASQSA-N 0.000 description 1
- KDQHCSHSVNHZRM-YFKPBYRVSA-N C[C@@H](C(O)O)NC(OC(C)(C)C)=O Chemical compound C[C@@H](C(O)O)NC(OC(C)(C)C)=O KDQHCSHSVNHZRM-YFKPBYRVSA-N 0.000 description 1
- GOBXYNQBDPHGSC-PCUGXKRQSA-N C[C@@H](CC(OC(C)(C)C)=O)c(cc1)cc2c1ccc(/C=C/C(C)(C)C(N=O)=O)c2 Chemical compound C[C@@H](CC(OC(C)(C)C)=O)c(cc1)cc2c1ccc(/C=C/C(C)(C)C(N=O)=O)c2 GOBXYNQBDPHGSC-PCUGXKRQSA-N 0.000 description 1
- SKNCHPCWDAMBFN-BLLXPEMXSA-N C[C@H](/C=C/C)C(C(C)([C@@H](Cc1ccccc1)C[O]1=C)C1=O)=O Chemical compound C[C@H](/C=C/C)C(C(C)([C@@H](Cc1ccccc1)C[O]1=C)C1=O)=O SKNCHPCWDAMBFN-BLLXPEMXSA-N 0.000 description 1
- RAFPTTZYSPQCQW-GTQGHAJQSA-N C[C@H]([C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1nc2cc(/C=C/C(C)(C)C3)ccc2cc1)=O)=O)=O)OC3=O)OC(C)(C)C Chemical compound C[C@H]([C@@H](C(N[C@@H](C)C(N(CCC1)N[C@@H]1C(N[C@H](C)c1nc2cc(/C=C/C(C)(C)C3)ccc2cc1)=O)=O)=O)OC3=O)OC(C)(C)C RAFPTTZYSPQCQW-GTQGHAJQSA-N 0.000 description 1
- YLWPIEBEYKCKSF-CJTWTEFWSA-N C[C@H](c(cc1)cc2c1ccc(/C=C/C(C)(C)C(OC)=O)c2)NC(OC(C)(C)C)=O Chemical compound C[C@H](c(cc1)cc2c1ccc(/C=C/C(C)(C)C(OC)=O)c2)NC(OC(C)(C)C)=O YLWPIEBEYKCKSF-CJTWTEFWSA-N 0.000 description 1
- JVIWLISXNJXXCT-NFZXAFRSSA-N C[C@H](c(cc1)cc2c1ccc([Br]=C)c2)N[S@](C1(C)C(C)C1)=[O]=C Chemical compound C[C@H](c(cc1)cc2c1ccc([Br]=C)c2)N[S@](C1(C)C(C)C1)=[O]=C JVIWLISXNJXXCT-NFZXAFRSSA-N 0.000 description 1
- FSNOCXHUCWVCML-XUIVZRPNSA-N C[C@H](c(cc1)cc2c1cnc(/C=C/C(C)(C)C(O)=O)c2)O Chemical compound C[C@H](c(cc1)cc2c1cnc(/C=C/C(C)(C)C(O)=O)c2)O FSNOCXHUCWVCML-XUIVZRPNSA-N 0.000 description 1
- RCJDUTYZIMHNMZ-AEIYXLGLSA-N C[C@H](c(cc1)nc2c1ccc(/C=C/C1(C(OC)=O)OCCOC1)c2)NC(OC(C)(C)C)=O Chemical compound C[C@H](c(cc1)nc2c1ccc(/C=C/C1(C(OC)=O)OCCOC1)c2)NC(OC(C)(C)C)=O RCJDUTYZIMHNMZ-AEIYXLGLSA-N 0.000 description 1
- DHZFWPJSELPFJW-FJOMSPGASA-N C[C@H](c(cc1)nc2c1ccc(/C=C/C1(CC(C)(C)OCC1)C(O)=O)c2)NC(OC(C)(C)C)=O Chemical compound C[C@H](c(cc1)nc2c1ccc(/C=C/C1(CC(C)(C)OCC1)C(O)=O)c2)NC(OC(C)(C)C)=O DHZFWPJSELPFJW-FJOMSPGASA-N 0.000 description 1
- MSYUJENHUZLORQ-SECBINFHSA-N C[C@H](c1cc2cc(C=C)ncc2cc1)O Chemical compound C[C@H](c1cc2cc(C=C)ncc2cc1)O MSYUJENHUZLORQ-SECBINFHSA-N 0.000 description 1
- WHAFLPMAEHDLTP-SSDOTTSWSA-N C[C@H](c1cc2cc(Cl)ncc2cc1)O Chemical compound C[C@H](c1cc2cc(Cl)ncc2cc1)O WHAFLPMAEHDLTP-SSDOTTSWSA-N 0.000 description 1
- MQSTVPYSRWDLGH-WEMWMXRPSA-N C[C@H](c1ccc(ccc(/C=C/COCOCC(O[C@@H](C(C)(C)F)C(N[C@@H](C)C(N2N[C@H]3CCC2)=O)=O)=O)c2)c2n1)NC3=O Chemical compound C[C@H](c1ccc(ccc(/C=C/COCOCC(O[C@@H](C(C)(C)F)C(N[C@@H](C)C(N2N[C@H]3CCC2)=O)=O)=O)c2)c2n1)NC3=O MQSTVPYSRWDLGH-WEMWMXRPSA-N 0.000 description 1
- MLWBWTSVRAQUKE-SNVBAGLBSA-N C[C@H](c1nc2cc(Br)ccc2cc1)NC(OC(C)(C)C)=O Chemical compound C[C@H](c1nc2cc(Br)ccc2cc1)NC(OC(C)(C)C)=O MLWBWTSVRAQUKE-SNVBAGLBSA-N 0.000 description 1
- NYEGMOOSJPMLTG-CYBMUJFWSA-N C[C@H](c1nc2cc(C)ccc2cc1)N(C)C(OC(C)(C)C)=O Chemical compound C[C@H](c1nc2cc(C)ccc2cc1)N(C)C(OC(C)(C)C)=O NYEGMOOSJPMLTG-CYBMUJFWSA-N 0.000 description 1
- AEQWZTUKJZWIOY-GVNUUABZSA-N C[C@](C(C1)C1OC(F)F)(C=C)C(O)=O Chemical compound C[C@](C(C1)C1OC(F)F)(C=C)C(O)=O AEQWZTUKJZWIOY-GVNUUABZSA-N 0.000 description 1
- AZRJVKWJVDJXMV-SECBINFHSA-N C[C@](COC(F)(F)F)(C=C)C(C1CC1)=O Chemical compound C[C@](COC(F)(F)F)(C=C)C(C1CC1)=O AZRJVKWJVDJXMV-SECBINFHSA-N 0.000 description 1
- BEDUADNIFZPRFN-UHFFFAOYSA-N C[NH+](C(C(CO)C1CCOCC1)=O)[O-] Chemical compound C[NH+](C(C(CO)C1CCOCC1)=O)[O-] BEDUADNIFZPRFN-UHFFFAOYSA-N 0.000 description 1
- MFHFFNAJUCCUIS-UHFFFAOYSA-N Cc1c(C(O)OC(c2c(C)cccc2N=O)=N)c(N=O)ccc1 Chemical compound Cc1c(C(O)OC(c2c(C)cccc2N=O)=N)c(N=O)ccc1 MFHFFNAJUCCUIS-UHFFFAOYSA-N 0.000 description 1
- MOEWRAKNXMILKB-UHFFFAOYSA-N Clc1nc(cc(cc2)Br)c2cc1 Chemical compound Clc1nc(cc(cc2)Br)c2cc1 MOEWRAKNXMILKB-UHFFFAOYSA-N 0.000 description 1
- VGBAYGFELCUXBS-UHFFFAOYSA-N OC(C1OCCOC1)=O Chemical compound OC(C1OCCOC1)=O VGBAYGFELCUXBS-UHFFFAOYSA-N 0.000 description 1
- PNKVYNRCKMOPHC-LURJTMIESA-N OC([C@H](C1CCCC1)N=O)=O Chemical compound OC([C@H](C1CCCC1)N=O)=O PNKVYNRCKMOPHC-LURJTMIESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657562P | 2012-06-08 | 2012-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2894269T3 true ES2894269T3 (es) | 2022-02-14 |
Family
ID=48626704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18155377T Active ES2894269T3 (es) | 2012-06-08 | 2013-06-07 | Inhibidores macrocíclicos de los virus flaviviridae |
| ES13729240.5T Active ES2672480T3 (es) | 2012-06-08 | 2013-06-07 | Inhibidores macrocíclicos de virus Flaviviridae |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13729240.5T Active ES2672480T3 (es) | 2012-06-08 | 2013-06-07 | Inhibidores macrocíclicos de virus Flaviviridae |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US9062092B2 (https=) |
| EP (2) | EP3392253B1 (https=) |
| JP (1) | JP6273268B2 (https=) |
| KR (1) | KR102185152B1 (https=) |
| CN (1) | CN104781261B (https=) |
| AP (1) | AP2015008189A0 (https=) |
| AR (1) | AR091279A1 (https=) |
| AU (1) | AU2013270670B2 (https=) |
| BR (1) | BR112014030639A2 (https=) |
| CA (1) | CA2875690C (https=) |
| CL (1) | CL2014003337A1 (https=) |
| CR (1) | CR20150018A (https=) |
| EA (1) | EA027134B1 (https=) |
| EC (1) | ECSP15000435A (https=) |
| ES (2) | ES2894269T3 (https=) |
| IL (1) | IL236007B (https=) |
| IN (1) | IN2014MN02657A (https=) |
| MA (1) | MA37712B1 (https=) |
| MD (1) | MD20140135A2 (https=) |
| MX (1) | MX358372B (https=) |
| NO (1) | NO2885641T3 (https=) |
| NZ (1) | NZ703062A (https=) |
| PE (1) | PE20150862A1 (https=) |
| PH (1) | PH12014502739A1 (https=) |
| PL (1) | PL2861601T3 (https=) |
| PT (1) | PT2861601T (https=) |
| SG (2) | SG10201703969PA (https=) |
| SI (1) | SI2861601T1 (https=) |
| TW (1) | TWI616448B (https=) |
| UA (1) | UA115664C2 (https=) |
| UY (1) | UY34851A (https=) |
| WO (1) | WO2013185093A1 (https=) |
| ZA (1) | ZA201409215B (https=) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| PT2861604T (pt) | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
| BR112014030649A2 (pt) | 2012-06-08 | 2017-06-27 | Gilead Sciences Inc | inibidores macrocíclicos da flaviviridae vírus |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| PT3038601T (pt) | 2013-08-27 | 2020-06-30 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
| WO2015084741A2 (en) | 2013-12-02 | 2015-06-11 | Gilead Pharmasset Llc | Methods of treating hepatitis c virus infection in subjects with cirrhosis |
| TW201609785A (zh) | 2013-12-23 | 2016-03-16 | 吉李德製藥公司 | 固體型之抗病毒化合物 |
| EA030849B1 (ru) | 2014-01-06 | 2018-10-31 | Бристол-Маерс Сквибб Компани | ПИРРОЛИДИНИЛСУЛЬФОНОВЫЕ МОДУЛЯТОРЫ RORγ |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| EP3247378B8 (en) | 2015-01-09 | 2023-08-23 | Revolution Medicines, Inc. | Macrocyclic compounds that participate in cooperative binding and medical uses thereof |
| US9670205B2 (en) | 2015-03-04 | 2017-06-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| EP4242304A3 (en) | 2015-10-01 | 2024-02-07 | Revolution Medicines, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| WO2017184670A2 (en) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating zika virus infections |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| EA201892375A1 (ru) | 2016-05-27 | 2019-08-30 | Джилид Сайэнс, Инк. | Способы лечения инфекций, вызываемых вирусом гепатита b |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| JOP20170127A1 (ar) | 2016-06-02 | 2017-12-02 | Gilead Pharmasset Llc | صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| WO2018136559A1 (en) * | 2017-01-17 | 2018-07-26 | The Regents Of The University Of California | Methods for treating flaviviruses and zika infections |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| UY37581A (es) | 2017-02-02 | 2018-08-31 | Gilead Sciences Inc | Compuestos para el tratamiento de la infección por virus de la hepatitis b |
| WO2018172250A1 (en) | 2017-03-21 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2018232174A2 (en) * | 2017-06-16 | 2018-12-20 | Avalon Flaviviral Therapeutics (Hk) Limited | Compositions and methods for treating flavivirus infections |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN111051305A (zh) | 2017-08-22 | 2020-04-21 | 吉利德科学公司 | 治疗性杂环化合物 |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US20220274979A1 (en) | 2018-04-18 | 2022-09-01 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| AU2019297362B2 (en) | 2018-07-06 | 2022-05-26 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| BR112021012057A2 (pt) * | 2018-12-21 | 2021-10-19 | Revolution Medicines, Inc. | Compostos que participam de ligação cooperativa e usos dos mesmos |
| CN113412249A (zh) * | 2019-02-08 | 2021-09-17 | 大金工业株式会社 | 有机化合物的制造方法 |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmåder til at behandle HBV |
| AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| IL322454A (en) * | 2019-11-04 | 2025-09-01 | Revolution Medicines Inc | ras inhibitors |
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| JP7778685B2 (ja) * | 2020-04-30 | 2025-12-02 | 富士フイルム富山化学株式会社 | ピラジン誘導体と他のコロナウイルス感染症治療薬とを組み合わせてなるコロナウイルス感染症治療剤 |
| EP4192474B1 (en) | 2020-08-07 | 2025-09-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| GB202207348D0 (en) | 2022-05-19 | 2022-07-06 | Cypralis Ltd | Macrocyclic compounds and uses thereof |
| CN115677482A (zh) * | 2022-11-22 | 2023-02-03 | 上海吉奉生物科技有限公司 | 一种手性α-羟基酸的合成方法 |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62193147A (ja) | 1986-02-19 | 1987-08-25 | Toshiba Corp | 半導体装置の製造方法 |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| AR006514A1 (es) * | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| EP1229910A4 (en) | 1999-10-04 | 2003-10-01 | Merck & Co Inc | integrin |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US20050159345A1 (en) | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
| PE20060481A1 (es) | 2004-06-30 | 2006-06-19 | Schering Corp | N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas |
| NZ564326A (en) | 2005-06-16 | 2010-01-29 | Cv Therapeutics Inc | Prodrugs of A2B adenosine receptor antagonists |
| AU2006259348B2 (en) * | 2005-06-17 | 2010-07-22 | Novartis Ag | Use of sanglifehrin in HCV |
| CL2008003384A1 (es) * | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| WO2009088256A2 (ko) | 2008-01-09 | 2009-07-16 | Konkuk University Industrial Cooperation Corp | 배큘로바이러스-기반 백신 |
| US20100080770A1 (en) * | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| SI2382198T1 (sl) * | 2008-12-23 | 2013-11-29 | Janssen Pharmaceuticals, Inc. | Postopek in vmesne spojine za pripravo makrocikličnega inhibitorja HCV proteaze |
| MX2012008211A (es) | 2010-01-15 | 2012-08-08 | Gilead Sciences Inc | Inhibidores de virus flaviviridae. |
| WO2011098808A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| GB201008123D0 (en) | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| EP2618665A4 (en) | 2010-09-21 | 2014-08-20 | Merck Sharp & Dohme | HCV NS3 proteinase inhibitor |
| PY1153144A (es) * | 2010-12-10 | 2015-01-01 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae |
| BR112014030649A2 (pt) | 2012-06-08 | 2017-06-27 | Gilead Sciences Inc | inibidores macrocíclicos da flaviviridae vírus |
| SG11201408093PA (en) | 2012-06-08 | 2015-01-29 | Glenmark Pharmaceuticals Sa | Amides of 2-amino-4-arylthiazole compounds and their salts |
| PT2861604T (pt) | 2012-06-08 | 2017-05-05 | Gilead Sciences Inc | Inibidores macrocíclicos de vírus flaviridae |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
-
2013
- 2013-06-05 AR ARP130101987 patent/AR091279A1/es unknown
- 2013-06-06 TW TW102120164A patent/TWI616448B/zh active
- 2013-06-06 UY UY0001034851A patent/UY34851A/es not_active Application Discontinuation
- 2013-06-07 PL PL13729240T patent/PL2861601T3/pl unknown
- 2013-06-07 SI SI201331014T patent/SI2861601T1/en unknown
- 2013-06-07 KR KR1020157000179A patent/KR102185152B1/ko active Active
- 2013-06-07 IN IN2657MUN2014 patent/IN2014MN02657A/en unknown
- 2013-06-07 PE PE2014002395A patent/PE20150862A1/es not_active Application Discontinuation
- 2013-06-07 MA MA37712A patent/MA37712B1/fr unknown
- 2013-06-07 MX MX2014014765A patent/MX358372B/es active IP Right Grant
- 2013-06-07 MD MDA20140135A patent/MD20140135A2/ro not_active Application Discontinuation
- 2013-06-07 ES ES18155377T patent/ES2894269T3/es active Active
- 2013-06-07 US US13/913,288 patent/US9062092B2/en active Active
- 2013-06-07 EP EP18155377.7A patent/EP3392253B1/en active Active
- 2013-06-07 EP EP13729240.5A patent/EP2861601B1/en active Active
- 2013-06-07 ES ES13729240.5T patent/ES2672480T3/es active Active
- 2013-06-07 AU AU2013270670A patent/AU2013270670B2/en active Active
- 2013-06-07 BR BR112014030639A patent/BR112014030639A2/pt not_active Application Discontinuation
- 2013-06-07 EA EA201492188A patent/EA027134B1/ru not_active IP Right Cessation
- 2013-06-07 SG SG10201703969PA patent/SG10201703969PA/en unknown
- 2013-06-07 AP AP2015008189A patent/AP2015008189A0/xx unknown
- 2013-06-07 NZ NZ703062A patent/NZ703062A/en not_active IP Right Cessation
- 2013-06-07 CA CA2875690A patent/CA2875690C/en active Active
- 2013-06-07 SG SG11201408064PA patent/SG11201408064PA/en unknown
- 2013-06-07 WO PCT/US2013/044812 patent/WO2013185093A1/en not_active Ceased
- 2013-06-07 PT PT137292405T patent/PT2861601T/pt unknown
- 2013-06-07 CN CN201380040628.8A patent/CN104781261B/zh active Active
- 2013-06-07 JP JP2015516258A patent/JP6273268B2/ja active Active
- 2013-07-06 UA UAA201413748A patent/UA115664C2/uk unknown
- 2013-08-16 NO NO13830006A patent/NO2885641T3/no unknown
-
2014
- 2014-11-30 IL IL236007A patent/IL236007B/en active IP Right Grant
- 2014-12-05 CL CL2014003337A patent/CL2014003337A1/es unknown
- 2014-12-05 PH PH12014502739A patent/PH12014502739A1/en unknown
- 2014-12-15 ZA ZA2014/09215A patent/ZA201409215B/en unknown
-
2015
- 2015-01-07 EC ECIEPI2015435A patent/ECSP15000435A/es unknown
- 2015-01-19 CR CR20150018A patent/CR20150018A/es unknown
- 2015-05-21 US US14/719,242 patent/US9642889B2/en active Active
-
2016
- 2016-04-08 US US15/094,777 patent/US20160220633A1/en not_active Abandoned
-
2017
- 2017-02-02 US US15/423,469 patent/US10472392B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2894269T3 (es) | Inhibidores macrocíclicos de los virus flaviviridae | |
| AU2013270672B2 (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| CN103403009B (zh) | 黄病毒科病毒的大环抑制剂 | |
| KR20150040266A (ko) | 플라비바이러스과 바이러스의 마크로시클릭 저해인자 | |
| HK1262165B (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| HK1262165A1 (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| HK1209731B (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| HK1209730B (en) | Macrocyclic inhibitors of flaviviridae viruses |